Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Research & Development (2017 - 2025)

Historic Research & Development for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to $13.2 million.

  • Organogenesis Holdings' Research & Development rose 2781.32% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year decrease of 935.44%. This contributed to the annual value of $50.3 million for FY2024, which is 1327.4% up from last year.
  • Per Organogenesis Holdings' latest filing, its Research & Development stood at $13.2 million for Q3 2025, which was up 2781.32% from $10.4 million recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' Research & Development peaked at $15.6 million during Q2 2024, and registered a low of $6.2 million during Q1 2021.
  • Over the past 5 years, Organogenesis Holdings' median Research & Development value was $10.5 million (recorded in 2023), while the average stood at $10.5 million.
  • As far as peak fluctuations go, Organogenesis Holdings' Research & Development surged by 14138.58% in 2021, and later tumbled by 3330.98% in 2025.
  • Organogenesis Holdings' Research & Development (Quarter) stood at $8.3 million in 2021, then skyrocketed by 37.95% to $11.4 million in 2022, then increased by 3.29% to $11.8 million in 2023, then dropped by 2.04% to $11.5 million in 2024, then increased by 14.67% to $13.2 million in 2025.
  • Its Research & Development was $13.2 million in Q3 2025, compared to $10.4 million in Q2 2025 and $10.6 million in Q1 2025.